Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Conditas Biotechnology Group has signed an exclusive US business development agreement with SYN|thesis med chem for medicinal chemistry and drug discovery services.
Subscribe to our email newsletter
Conditas will represent the Melbourne and Shanghai based company as its agent for business development and sales of services in the US.
The Conditas Group Jr. founder and principal Leland L Johnson said they would benefit from SYN|thesis by receiving efficient and cost-effective synthetic chemistry resources, besides receiving medicinal chemistry and drug discovery services.
"This new partnership broadens our offerings across the biology and chemistry spectrum and allows us to give our customers a more expansive suite of services," Johnson added.